DPI-221

From WikiMD's WELLNESSPEDIA

DPI-221 is a synthetic opioid drug that acts as a highly selective agonist for the δ-opioid receptor. It was developed for its potential use in treating conditions such as pain, depression, and anxiety.

Pharmacology[edit]

DPI-221 is known for its high selectivity towards the δ-opioid receptor, which distinguishes it from other opioids that typically target the μ-opioid receptor. This selectivity is significant because δ-opioid receptor agonists are believed to produce fewer side effects compared to μ-opioid receptor agonists, such as reduced risk of respiratory depression and addiction.

Mechanism of Action[edit]

DPI-221 binds to and activates the δ-opioid receptor, which is a G protein-coupled receptor (GPCR). Activation of this receptor leads to a cascade of intracellular events that result in the modulation of neurotransmitter release and ultimately produce analgesic and mood-enhancing effects.

Potential Therapeutic Uses[edit]

Pain Management[edit]

Due to its analgesic properties, DPI-221 has been studied for its potential use in managing various types of pain, including chronic pain and neuropathic pain. Its selective action on the δ-opioid receptor may offer pain relief with a lower risk of side effects commonly associated with traditional opioids.

Depression and Anxiety[edit]

Research has indicated that δ-opioid receptor agonists like DPI-221 may have antidepressant and anxiolytic effects. This makes DPI-221 a candidate for the treatment of major depressive disorder and generalized anxiety disorder.

Side Effects and Safety[edit]

While DPI-221 is designed to minimize the side effects associated with traditional opioids, it is not entirely free from adverse effects. Common side effects may include nausea, dizziness, and headache. Long-term safety and efficacy studies are required to fully understand the risk profile of DPI-221.

Research and Development[edit]

DPI-221 is still under investigation, and its clinical applications are yet to be fully realized. Ongoing research aims to better understand its pharmacokinetics, pharmacodynamics, and potential therapeutic benefits.

See Also[edit]

References[edit]


Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=DPI-221&oldid=5805281"